IDEAYA Biosciences/$IDYA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IDEAYA Biosciences
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Ticker
$IDYA
Sector
Primary listing
Employees
145
Headquarters
Website
IDYA Metrics
BasicAdvanced
$2.7bn
-
-$1.58
-0.04
-
Price and volume
Market cap
$2.7bn
Beta
-0.04
52-week high
$39.28
52-week low
$20.50
Average daily volume
1m
Financial strength
Current ratio
10.737
Quick ratio
10.454
Long term debt to equity
3.014
Total debt to equity
3.051
Profitability
EBITDA (TTM)
-180.68
Gross margin (TTM)
-50.73%
Net profit margin (TTM)
-62.17%
Operating margin (TTM)
-81.44%
Revenue per employee (TTM)
$1,550,000
Management effectiveness
Return on assets (TTM)
-10.76%
Return on equity (TTM)
-14.28%
Valuation
Price to revenue (TTM)
12.019
Price to book
2.87
Price to tangible book (TTM)
2.87
Price to free cash flow (TTM)
-30.793
Free cash flow yield (TTM)
-3.25%
Free cash flow per share (TTM)
-0.993
Growth
Revenue change (TTM)
3,118.14%
Earnings per share change (TTM)
-56.23%
3-year revenue growth (CAGR)
68.07%
3-year earnings per share growth (CAGR)
0.54%
What the Analysts think about IDYA
Analyst ratings (Buy, Hold, Sell) for IDEAYA Biosciences stock.
IDYA Financial Performance
Revenues and expenses
IDYA Earnings Performance
Company profitability
IDYA News
AllArticlesVideos
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
MarketBeat·3 weeks ago
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
MarketBeat·3 weeks ago
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
MarketBeat·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs